Safety and Efficacy of an 11β-Hydroxysteroid Dehydrogenase Type-1 Inhibitor (AZD4017) in Idiopathic Intracranial Hypertension
Creator
Keira Markey; Ryan Ottridge; James Mitchell; Caroline Rick; Rebecca Woolley; Natalie Ives; Tim Matthews; Anita Krishnan; Pushkar Shah; William Scotton; Susan Mollan; Alex Sinclair
Affiliation
(KM) (JM) (WS) (AS) Institute of Metabolism and Systems Research, Edgbaston, United Kingdom; (RO) (CR) (RW) (NI) Birmingham Clinical Trials Unit, University of Birmingham, Edgbaston, United Kingdom; (TM) (SM) University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; (AK) The Walton Centre Nhs Foundation Trust, Liverpool, United Kingdom; (PS) NHS Glasgow and Greater Clyde, Glasgow, United Kingdom
Subject
High Intracranial Pressure/headache; Pseudotumor Cerebri; Perimetry
Description
Pharmacological therapy in IIH is limited. We investigated the safety, tolerability and efficacy of a novel drug, an 11β-hydroxysteroid dehydrogenase type-1 inhibitor (AZ4017).
Date
2018-04
Language
eng
Format
video/mp4
Type
Image/MovingImage
Source
2018 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of
NANOS Annual Meeting 2018: Scientific Platform, Session I
